Clinical trial NCT05742607: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Official title: Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Non Small Cell Lung Cancer
Lead sponsor: Innate Pharma
Sponsor class: INDUSTRY
First posted: 2023-02-24
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).

Detailed description: This is an open-label, single-arm multicenter study. Eligible patients will be enrolled and will receive IPH5201 + Durvalumab + standard of care chemotherapy before surgery followed by IPH5201 + Durvalumab post-surgery.

Eligibility criteria: Inclusion Criteria:

1. Newly diagnosed and previously untreated patients with histologically or cytologically documented NSCLC resectable (Stage IIA to Stage IIIA) disease (according to Version 8 of IASLC Staging Manual in Thoracic Oncology 2016.
2. WHO Performance Status or Eastern Cooperative Oncology Group of 0 or 1.
3. Adequate organ and marrow function.
4. Must have a life expectancy of at least 12 weeks.
5. Body weight \> 35 kg.
6. Females of childbearing potential should use an acceptable method of contraception from the time of screening throughout the total duration of the study.
7. Negative pregnancy test (serum or urine) for women of childbearing potential.
8. Provision of tumor samples (newly acquired \[preferred\] or archival tumor tissue \[≤ 6 months old\]) to confirm Programmed Death-Ligand 1 status, Epidermal Growth Factor Receptor, or Anaplastic Lymphoma Kinase status.
9. Provision of tumor samples appropriate for exploratory biomarker analyses.
10. Patients will be suitable for inclusion if the planned surgery to be performed will be lobectomy, sleeve resection, or bilobectomy, as determined by the attending surgeon based on the baseline findings.
11. A pre- or post-bronchodilator FEV1 of 1.0 L and DLCO \> 40% postoperative predicted value.

Exclusion Criteria:

1. Participants with sensitising EGFR mutations or ALK translocations.
2. History of allogeneic organ transplantation.
3. Active or prior documented autoimmune or inflammatory disorders.
4. Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active ILD, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement.
5. History of any grade of venous or arterial thromboembolic events including cerebrovascular accident, transient ischemic attack, or unstable angina pectoris within 6 months prior to enrollment.
6. History of another primary malignancy.
7. Patients with small-cell lung cancer or mixed small-cell lung cancer.
8. History of active primary immunodeficiency.
9. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive HBsAg result) and HCV. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
10. Patients who have preoperative radiotherapy treatment as part of their care plan.
11. Patients who require or may require pneumonectomy, segmentectomies, or wedge resections, as assessed by their surgeon, to obtain potentially curative resection of primary tumor.
12. QTc interval ≥ 470 ms (NOTE: If prolonged, then 2 additional ECGs should be obtained and the average QTcF interval should be used to determine eligibility).
13. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
14. Any medical contraindication to treatment with chemotherapy as listed in the local labelling.
15. Patients with moderate or severe cardiovascular disease.
16. Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
17. Receipt of live attenuated vaccine within 30 days prior to the first dose of study interventions.
18. Major surgical procedure (as defined by the Investigator) within 30 days prior to the first dose of study drugs.
19. Prior exposure to immune-mediated therapy.
20. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs.
21. Participation in another clinical study with an investigational product administered within 30 days prior to enrolment.
22. Previous study drugs (durvalumab, IPH5201) assignment in the present study.
23. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of study drugs administration.
24. Involvement in the planning and/or conduct of the study (applies to both company staff and/or staff at the study site).
25. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
26. Exclusion criteria for participation in the optional (DNA) genetics research component.

Primary outcomes:
measure: Pathological Complete Response (pCR)
timeFrame: 16 weeks after the first dose of study intervention.
measure: Adverse events (AEs) and serious adverse events (SAEs)
timeFrame: Until Day 90 after the last dose of study interventions.
Secondary outcomes:
measure: Event-Free Survival (EFS)
timeFrame: Up to approximately 2 years.
measure: Disease Free Survival (DFS)
timeFrame: Up to approximately 2 years.
measure: Surgical resection
timeFrame: Approximately 16 weeks after the first dose of study intervention.
measure: Major Pathological Response (mPR)
timeFrame: Approximately 16 weeks after the first dose of study intervention.
measure: Objective Response Rate (ORR)
timeFrame: Up to approximately 4 months adjuvant.
measure: Overall Survival (OS)
timeFrame: Up to approximately 2 years.
measure: PK of IPH5201 in combination with durvalumab +/- chemotherapy
timeFrame: Up to approximately 4 months adjuvant.
measure: Anti-study drug antibodies (ADA)
timeFrame: Up to approximately 4 months adjuvant.
Other outcomes:
Locations:
city: Saint Petersburg
country: United States
facility: St. Anthony's Hospital - BayCare Health System
state: Florida
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center & Research Institute
state: Florida
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
city: Lake Success
country: United States
facility: Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics
state: New York
city: Houston
country: United States
facility: Millennium Research & Clinical Development
state: Texas
city: Madison
country: United States
facility: UW Carbone Cancer Center - Cancer Connect
state: Wisconsin
city: Angers
country: France
facility: Angers University Hospital Center
city: Caen
country: France
facility: University Hospital Center Caen
city: Lille
country: France
facility: Hospital Calmette
city: Limoges
country: France
facility: CHU de Limoges
city: Lyon
country: France
facility: Leon Berard Center
city: Marseille
country: France
facility: Marseille University Hospital Center - North Hospital
city: Rennes
country: France
facility: Rennes University Hospital Center - Hospital Pontchaillou
city: Rouen
country: France
facility: Charles Nicolle Hospital
city: Villejuif
country: France
facility: Gustave Roussy
city: Athens
country: Greece
facility: Henry Dunant Hospital Center
city: Athens
country: Greece
facility: University General Hospital "Attikon"
city: Ioánnina
country: Greece
facility: University General Hospital of Ioannina
city: Patras
country: Greece
facility: University General Hospital of Patras
city: Budapest
country: Hungary
facility: Koranyi National Institute of Pulmonology, 14th Department of Pulmonology
city: Farkasgyepu
country: Hungary
facility: Veszprem County Pulmonology Institute
city: Győr
country: Hungary
facility: Petz Aladar University Teaching Hospital, Department of Pulmonology
city: Szolnok
country: Hungary
facility: Jasz-Nagykun-Szolnok County Hetenyi Geza Hospital-Clinic, Department of Oncology
city: Torokbalint
country: Hungary
facility: Pulmonology Institute Torokbalint
city: Bialystok
country: Poland
facility: University Teaching Hospital in Bialystok, 2nd Department of Lung Diseases and Tuberculosis
city: Krąków
country: Poland
facility: John Paul II Specialist Hospital in Krakow
city: Lublin
country: Poland
facility: Mandziuk Slawomir - Specialist Medical Practice
city: Poznań
country: Poland
facility: Eugenia and Janusz Zeyland Wielkopolskie Centre of Pulmonology and Thoracic Surgery
city: Prabuty
country: Poland
facility: Specialist Hospital in Prabuty Sp. z o.o. (LLC)
city: Warsaw
country: Poland
facility: Military Institute of Medicine - National Research Institute
Study officials:
References: